| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00093-7602-57 | 00093-7602 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | Oct 31, 2018 | In Use |
| 42737-0105-14 | 42737-0105 | temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec 31, 2018 | Jan 24, 2019 | In Use |
| 72789-0509-15 | 72789-0509 | PredniSONE | PredniSONE Tablets, USP, 20 mg | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 22, 2025 | In Use | |
| 80425-0473-01 | 80425-0473 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 29, 2024 | In Use | |
| 10631-0134-31 | 10631-0134 | Isotretinoin | Absorica | 35.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Feb 17, 2015 | In Use | |
| 54868-1629-01 | 54868-1629 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Jul 5, 2007 | In Use | ||
| 00115-1675-72 | 00115-1675 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sep 21, 2016 | Apr 3, 2019 | In Use |
| 60505-4764-06 | 60505-4764 | Abiraterone acetate | Abiraterone acetate | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Jul 16, 2021 | In Use | |
| 68001-0265-22 | 68001-0265 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Nov 14, 2013 | In Use | |
| 68382-0913-84 | 68382-0913 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
| 54868-0173-00 | 54868-0173 | methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous | Mar 26, 2003 | In Use | |
| 63323-0142-12 | 63323-0142 | Ifosfamide | Ifosfamide | 1.0 g/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jan 28, 2003 | In Use | |
| 52549-4118-05 | 52549-4118 | Fluorouracil | Fluorouracil | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Mar 5, 2010 | In Use | |
| 55154-0450-05 | 55154-0450 | Metoclopramide Hydrochloride | Metoclopramide Hydrochloride | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Dec 10, 1993 | In Use | |
| 55513-0326-01 | 55513-0326 | rituximab-arrx | Riabni | 500.0 mg/50mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 6, 2021 | In Use | |
| 57962-0420-28 | 57962-0420 | Ibrutinib | IMBRUVICA | 420.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Feb 16, 2018 | In Use | |
| 63459-0920-59 | 63459-0920 | tbo-filgrastim | GRANIX | 480.0 ug/1.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 7, 2018 | Sep 30, 2026 | In Use |
| 58468-7840-03 | 58468-7840 | Vandetanib | Caprelsa | 300.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Oral | Jul 25, 2011 | In Use | |
| 00009-0112-05 | 00009-0112 | Irinotecan hydrochloride | Camptosar | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec 30, 2024 | In Use | |
| 59572-0410-28 | 59572-0410 | Lenalidomide | Revlimid | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2009 | In Use | |
| 59676-0600-56 | 59676-0600 | Apalutamide | ERLEADA | 60.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Apr 1, 2019 | In Use | |
| 61919-0565-30 | 61919-0565 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 22, 2019 | In Use | |
| 00002-5562-60 | 00002-5562 | Selpercatinib | RETEVMO | 160.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, RET | Oral | Apr 10, 2024 | In Use | |
| 51144-0020-01 | 51144-0020 | ENFORTUMAB VEDOTIN | PADCEV | 20.0 mg/2mL | Immunotherapy | Drug Antibody Conjugate | Nectin-4 | Intravenous | Dec 18, 2019 | In Use | |
| 00173-0915-61 | 00173-0915 | Niraparib | ZEJULA | 300.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jun 27, 2023 | In Use |
Found 11888 results — Export these results
Home